Eynde, Jean Jacques Vanden published the artcileCOVID-19: failure of the DisCoVeRy clinical trial, and now-new hopes?, COA of Formula: C17H19N3O7S, the publication is Pharmaceuticals (2021), 14(7), 664, database is CAplus and MEDLINE.
The DisCoVeRy clin. trial aimed at the evaluation of four treatments for patients suffering from severe to critical COVID-19: Hydroxychloroquine, eventually associated with azithromycin; the combination lopinavir/ritonavir; the combination with the addition of interferon ¦Â-1a; remdesivir. The trial was discontinued due to the lack of pos. results. Meanwhile, many other potential options have been considered either to target the virus itself, the interactions with the host cells, or the cytokine storm frequently observed during the infection. Several of those options are briefly reviewed. They include vaccines, small mols., antibodies, and stem cells.
Pharmaceuticals published new progress about 71079-09-9. 71079-09-9 belongs to catalysis-chemistry, auxiliary class Salt,Carboxylic acid,Carbamidine,Amine,Benzene,Ester,Protease,Ser/Thr Protease, name is 2-(4-((4-Guanidinobenzoyl)oxy)phenyl)acetic acid methanesulfonic acid salt, and the molecular formula is C17H19N3O7S, COA of Formula: C17H19N3O7S.
Referemce:
https://courses.lumenlearning.com/boundless-chemistry/chapter/catalysis/,
Catalysis – Wikipedia